Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc.
TypeSubsidiary
Nasdaq: ALXN
IndustryPharmaceutical industry
Founded1992 (1992)
FounderLeonard Bell
HeadquartersBoston, Massachusetts, U.S.
Key peopleLeonard Bell (chairman)
Ludwig N. Hantson (CEO)
ProductsEculizumab (Soliris)
Ravulizumab (Ultomiris)
Asfotase alfa (Strensiq)
Sebelipase alfa (Kanuma)
Andexanet alfa (Andexxa)
RevenueIncrease US$6.069 billion (2020)
Decrease US$603 million (2020)
Total assetsIncrease US$18.103 billion (2020)
Total equityIncrease US$11.651 billion (2020)
Number of employees
2,525 (2020)
ParentAstraZeneca
Websitewww.alexion.com
Footnotes

Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in New Haven, Connecticut, specializing in orphan drugs for rare diseases.

Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa), used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.

With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.